Mallinckrodt PLC (NYSE: MNK) is one of 19 public companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Mallinckrodt PLC to similar businesses based on the strength of its analyst recommendations, valuation, dividends, institutional ownership, risk, earnings and profitability.
Valuation & Earnings
This table compares Mallinckrodt PLC and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Mallinckrodt PLC||$3.27 billion||$666.60 million||7.89|
|Mallinckrodt PLC Competitors||$2.57 billion||$977.16 million||-0.32|
Mallinckrodt PLC has higher revenue, but lower earnings than its rivals. Mallinckrodt PLC is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a summary of recent ratings for Mallinckrodt PLC and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Mallinckrodt PLC Competitors||65||307||951||27||2.70|
Mallinckrodt PLC currently has a consensus price target of $59.97, suggesting a potential upside of 85.32%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 27.12%. Given Mallinckrodt PLC’s stronger consensus rating and higher possible upside, analysts plainly believe Mallinckrodt PLC is more favorable than its rivals.
This table compares Mallinckrodt PLC and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Mallinckrodt PLC Competitors||-540.60%||-41.61%||-24.68%|
Insider & Institutional Ownership
97.4% of Mallinckrodt PLC shares are owned by institutional investors. Comparatively, 66.8% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by institutional investors. 0.5% of Mallinckrodt PLC shares are owned by insiders. Comparatively, 11.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Volatility and Risk
Mallinckrodt PLC has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500. Comparatively, Mallinckrodt PLC’s rivals have a beta of 0.89, meaning that their average stock price is 11% less volatile than the S&P 500.
Mallinckrodt PLC beats its rivals on 10 of the 13 factors compared.
Mallinckrodt PLC Company Profile
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.
Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with MarketBeat.com's FREE daily email newsletter.